000 | 01283 a2200397 4500 | ||
---|---|---|---|
005 | 20250514020204.0 | ||
264 | 0 | _c20011228 | |
008 | 200112s 0 0 eng d | ||
022 | _a0098-7484 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSchwetz, B A | |
245 | 0 | 0 |
_aFrom the Food and Drug Administration. _h[electronic resource] |
260 |
_bJAMA _cDec 2001 |
||
300 |
_a2660 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAdenine _xanalogs & derivatives |
650 | 0 | 4 | _aAdministration, Oral |
650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
650 | 0 | 4 |
_aCathartics _xadministration & dosage |
650 | 0 | 4 | _aDefibrillators, Implantable |
650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
650 | 0 | 4 | _aHIV-1 |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMonitoring, Ambulatory |
650 | 0 | 4 | _aOrganophosphonates |
650 | 0 | 4 |
_aOrganophosphorus Compounds _xtherapeutic use |
650 | 0 | 4 | _aPacemaker, Artificial |
650 | 0 | 4 | _aPharmaceutical Solutions |
650 | 0 | 4 |
_aPhosphates _xadministration & dosage |
650 | 0 | 4 | _aTenofovir |
650 | 0 | 4 | _aUnited States |
650 | 0 | 4 | _aUnited States Food and Drug Administration |
650 | 0 | 4 | _aViral Load |
650 | 0 | 4 |
_aWater-Electrolyte Imbalance _xchemically induced |
773 | 0 |
_tJAMA _gvol. 286 _gno. 21 _gp. 2660 |
|
999 |
_c11644335 _d11644335 |